|
Post by mnholdem on Jan 26, 2015 9:26:56 GMT -5
How's this for perfect timing?
seekingalpha.com/article/2849316-a-new-price-estimate-now-that-afrezza-is-launching
Excerpt from article:
Estimating sales based on unit sales of fast-acting injected insulins
Since the retail pricing is in line, making Afrezza competitive with existing products, we can learn a lot by looking at historical sales data for the other fast acting insulins currently on the market.
Luckily for us, this data is available online in Drugs.com's list of the top 100 U.S. bestselling drugs of 2013. The main fast-acting insulins that dominate this niche, Novolog from Novo Nordisk (NYSE:NVO) and Humalog from Lilly (NYSE:LLY) appear on this list in both their vial and pen forms. So we can quickly determine how many units they sold over the course of the year and what their total revenue was for those 2013 U.S. sales.
|
|
|
Post by otherottawaguy on Jan 26, 2015 9:27:57 GMT -5
Sounds like Dedendron (DNDN).. that went from 3 to 60 in a year and is now facing restructuring because of lack of market for 100K+ one off treatment.
OOG
|
|